Is vitamin D insufficiency associated with peripheral neuropathy?

Endocrinologist

Volumn 17, Issue 6, 2007, Pages 319-325

  Carlson, Amanda N ^a   Kenny, Anne M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Central nervous system; Neuropathy; Vitamin D

Indexed keywords

CALBINDIN; NEUROTRANSMITTER; NEUROTROPHIN; QR 333; QUERCETIN; UNCLASSIFIED DRUG; VITAMIN D;

CELL LINE; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; DRUG EFFECT; HORMONE ACTION; HUMAN; HYPOPARATHYROIDISM; NERVE CELL DEGENERATION; NERVE DEGENERATION; NERVE GROWTH; NEUROPROTECTION; OSSIFICATION; PERIPHERAL NEUROPATHY; PHOSPHATE METABOLISM; REVIEW; VITAMIN D DEFICIENCY;

EID: 37349043176     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181594284     Document Type: Review

References (101)

1. Boron W, Boulpaep E. Medical Physiology. Philadelphia: Saunders; 2003:1095-1097.
2. Henry H, Norman H. Vitamin D: metabolism and biological actions. Ann Rev Nutr. 1984;4:493-520.
3. Kiraly S, Kiraly M, Hawe R, et al. Vitamin D as a neuroactive substance: review. Sci World J. 2006;6:125-139.
4. Garcion E, Wion-Barbot N, Montero-Menei C, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13:100-105.
5. 3H1,25 dihydroxyvitamin D3 uptake by canine and rodent brain. Am J Physiol. 1983;E266-E271.
6. Stumpf W, Clark S, O'Brien L, et al. 1,25 Dihydroxyvitamin D3 sites of action in spinal cord and sensory ganglion. Anat Embryol. 1988; 177:307-310.
7. Stumpf W, O'Brien L. 1,25 Dihydroxyvitamin D3 sites of action in the brain. Histochemistry. 1987;87:393-406.
8. Stumpf W, Sar M, Clarke S. Brain target sites for 1,25 dihydroxyvitamin D3. Science. 1982;214:1403-1405.
9. Stumpf W, Sar M, Reid F, et al. Target cells for 1,25 dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science. 1979;206:1188-1190.
10. Balabanova S, Richter H, Antoniadis G, et al. 25-Hydroxyvitamin D, 24,25 dihydroxyvitamin D and 1,25 dihydroxyvitamin D in human cerebrospinal fluid. Klin Wochenschr. 1984;62:1086-1090.
11. Neveu I, Jehan F, Wion D. Alteration in the levels of 1,25 dihydroxyvitamin D3 and corticosterone found in experimental diabetes reduces nerve growth factor (NGF) gene expression in vitro. Life Sci. 1992;50: 1769-1772.
12. Neveu I, Naveilhan P, Jehan F, et al. 1,25 Dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Mol Brain Res. 1994;24:70-76.
13. Kliewer S, Umesono K, Mangelsdorf D, et al. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signaling. Nature. 1992;355:446-449.
14. Baas D, Prufer K, Ittel M, et al. Rat oligodendrocytes express the vitamin D receptor and respond to 1,25 dihydroxyvitamin D3. Glia. 2000;31:59-68.
15. Clemens T, Garrett K, Zhou X, et al. Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology. 1988;122:1224 -1230.
16. Lewen G, Mendell L. Nerve growth factor and nociception. Trends Neurosci. 1993;16:353-359.
17. Ross T, Moss V, Prahl J, et al. A nuclear protein essential for binding of rat 1,25 dihydroxyvitamin D3 receptor to its response elements. Proc Natl Acad Sci U S A. 1992;89:256-260.
18. Segaert S, Bouillon R. Vitamin D and regulation of gene expression. Curr Opin Clin Nutr Metab Care. 1998;1(4):3447-3454.
19. Johnson J, Grande J, Windebank A, et al. 1,25-Dihydroxyvitamin D3 receptors in developing dorsal root ganglia of fetal rats. Dev Brain Res. 1996;92:120-124.
20. Langub M, Herman J, Malluche H, et al. Evidence of functional vitamin D receptors in rat hippocampus. Neuroscience. 2001;104: 49-56.
21. MacDonald P, Baudino T, Tokumaru H, et al. Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. Steroids. 2001;666:171-176.
22. Prufer K, Veenstra T, Jirikowski G, et al. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the rat brain and spinal cord. J Chem Neuroanat. 1999;16:135-145.
23. Jia Z, Nemere I. Immunochemical studies on the putative plasmalemma receptor for 1,25-dihydroxyvitamin D3, II: chick kidney and brain. Steroids. 1999;64:541-550.
24. Chesney R. Rickets: an old form for a new century. Pediatr Int. 2003;45:509-511.
25. Wharton B, Bishop N. Rickets. Lancet. 2003;362:1389-1400.
26. Latham N, Anderson C, Reid I. Effects of vitamin D supplementation on strength, physical performance and falls in older persons: a systematic review. Am Geriatr Soc. 2003;51:1219-1226.
27. Barde Y. Trophic factors and neuronal survival. Neuron. 1987;2:1525-1534.
28. Mobley W, Rutkowski J, Tennekoon G, et al. Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science. 1985;229:284-286.
29. Sofroniew M, Howe C, Mobley W. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24:1217-1281.
30. Thoenen H, Barde Y. Physiology of nerve growth factor. Physiol Rev. 1980;60:1284-1335.
31. Carswell S, Hoffman E, Clopton-Hartpence K, et al. Induction of NGF by isoproterenol, 4-methylcatechol, and serum occurs by three distinct mechanisms. Mol Brain Res. 1992;15:145-150.
32. Carswell S, Wilcox H, Clopton-Hartpence K, et al. Multiple cellular pathways of induction of NGF by 1,25 dihydroxvitamin D3, TPA, serum, and 4-methylcatechol. Soc Neurosci Abstr. 1992;18:777.
33. Musiol I, Feldman D. 1,25 Dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs. Endocrinology. 1997; 138:12-18.
34. Saporito M, Wilcox H, Hartpence K, et al. Pharmacological induction of nerve growth factor in adult rat brain. Exp Neurol. 1993;123:295-302.
35. Sonnenberg J, Luine V, Krey L, et al. 1,25 Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology. 1986;118:1433-1439.
36. Wion D, MacGrogan D, Neveu I, et al. 1,25 Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res. 1991;28:110-114.
37. Jehan F, Neveu I, Barbot N, et al. MC903, an analogue of 1,25 dihydroxyvitamin D3, increases the synthesis of nerve growth factor. Eur J Pharmacol. 1991;208:189-191.
38. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37:889.
39. Arenas B, Trupp M, Akerud P, et al. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron. 1995;15:1465-1473.
40. Beck K, Valverde J, Alexi T. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature. 1995;373:339-341.
41. Tomac A, Lindquist E, Lin L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature. 1995;373:335-339.
42. Henderson C, Phillips H, Pollock R. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994; 266:1062-1064.
43. Oppenheim M, Houenou L, Johnson J. Nature. 1995;373:344-346.
44. Yan Q, Matheson C, Lopex O. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature. 1995;341-344.
45. Naveilhan P, Neveu I, Wion D, et al. 1,25 Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport. 1996;7:2171-2175.
46. Hengerer B, Lindholm D, Ruther U, et al. Lesion induced increase in nerve growth factor mRNA is mediated by c-fos. Proc Natl Acad Sci U S A. 1990;87:3899-3903.
47. Mocchetti I, DeBernardi M, Szekely A, et al. Regulation of nerve growth factor biosynthesis by beta-adrenergic receptor activation in astrocytoma cells: a potential role of c-fos protein. Proc Natl Acad Sci U S A. 1989;86:3891-3985.
48. Morgan J, Curran T. Role of ion flux in the control of c-fos expression. Nature. 1996;322:552-555.
49. Naveilhan P, Neveu I, Baudet C, et al. 1,25 Dihydroxyvitamin D3 regulates the expression of the low-affinity neurotrophin receptor. Mol Brain Res. 1996;41:259-268.
50. Garcion E, Nataf S, Berod A, et al. 1,25 Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Mol Brain Res. 1997;45:255-267.
51. Garcion E, Sindji L, Montero-Menei C, et al. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25 dihydroxyvitamin D3. Glia. 1998;22:282-294.
52. Garcion E, Sindji L, Leblondel G, et al. 1,25 Dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999;73:859-866.
53. Garcion E, Thanh X, Bled F, et al. 1,25 Dihydroxyvitamin D3 regulates gamma-glutamyl transpeptidase activity in rat brain. Neurosci Lett. 1996;216:183-186.
54. Pirart J. Why don't we teach and treat diabetic patients better? Diabetes Care. 1978;1:139-140.
55. Wright J. Review of the symptomatic treatment of diabetic neuropathy. Pharmacotherapy. 1994;14:689-697.
56. DeMott T, Richardson J, Thies S, et al. Falls and gait characteristics among older persons with peripheral neuropathy. Am J Phys Med Rehabil. 2007;86:125-132.
57. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2005.
58. Hellweg R, Hartung H. Endogenous levels of nerve growth factor are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res. 1990;26:258-267.
59. Hellweg R, Wohrle M, Hartung H, et al. Diabetes mellitus-associated decrease in nerve growth factor levels is reversed by allogenic pancreatic islet transplantation. Neurosci Lett. 1991;125:1-4.
60. Anand P, Terenghi G, Warner G, et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med. 1996;6:703-707.
61. Apfel S, Arezzo J, Brownlee M, et al. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol. 1991;29:87-90.
62. Fukuoka M, Sakurai K, Ohta T, et al. Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes. Skin Pharmacol Appl Skin Physiol. 2001;14:226-233.
63. Schneider L, Schedl H, McCain T, et al. Experimental diabetes reduces circulating 1,25 dihydroxyvitamin D in the rat. Science. 1977;196: 1452-1454.
64. Seino Y, Sierra R, Sonn Y, et al. The duodenal 1,25 dihydroxyvitamin D3 receptor in rats with experimentally induced diabetes. Endocrinology. 1983;113:1721-1725.
65. Haddad J, Walgate J. 25-Hydroxyvitamin D transport in human plasma: isolation and partial characterization of calcifidol-binding protein. J Biol Chem. 1976;251:4083.
66. Mansford R, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968; 1968:670.
67. DeNicola A, Fridman O, DelCastillo E, et al. The influence of streptozotocin diabetes on adrenal function in male rats. Horm Metab Res. 1976;8:388.
68. Kaplon R, Haussler M, Pak C. The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest. 1977;59:756-760.
69. Schneider L, Wasserman R, Schedl H. Depressed duodenal calcium absorption in the diabetic rat: restoration by Solanum malacoxylon. Endocrinology. 1975;97:649-653.
70. Haussler M, Wasserman R, McCain T, et al. Life Sci. 1976;18:1049.
71. Coratelli P, Petrarulo F, Giannattasio M, et al. Clinical and metabolic effects of long-term treatment with 25 (OH) D3 in hemodialysis. Contrib Nephrol. 1985;49:20-31.
72. Jurist J. In vivo determination of the elastic response of bone, II: ulnar resonant frequency in osteoporotic, diabetic, and normal subjects. Phys Med Biol. 1970;15:427-434.
73. LaVeccia C, Braga C, Negri E, et al. Intake of selected micronutrients and risk of colorectal cancer. Int J Cancer. 1997;73:523-530.
74. Levin M, Boisseau V, Avioli L. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. N Engl J Med. 1976;294:241.
75. Neumann H, Arnold W. Incidence of diabetes mellitus in 343 cases of trunk osteoporosis. Zentralbl Chir. 1971;96:1395-1401.
76. Wu K, Schubeck K, Frost H, et al. Haversian bone formation rates determined by a new method in a mastodon, and in human diabetes mellitus and osteoporosis. Calcif Tissue Res. 1970;6:204.
77. Gnahn H, Hefti F, Heumann R, et al. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiologic role of NGF in the brain? Dev Brain Res. 1983;9:45-52.
78. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci. 1986;6:2155-2162.
79. Fernyhough P, Diemel L, Brewster W, et al. Altered neurotrophin mRNA in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem. 1995;64:1231-1237.
80. Riaz S, Malcangio M, Miller M, et al. A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozocin-diabetic rats. Diabetologia. 1999;42:1308-1313.
81. Alexianu M, Ho B, Mohamed H, et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1994;36:846-858.
82. ++ dependent processes as mediators of neurotoxicity. Neurotoxicology. 1992;13:139-148.
83. Sutherland M, Somerville M, Yoong L, et al. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin 28K mRNA levels. Mol Brain Res. 1992;13:239-250.
84. Siklos L, Engelhardt J, Harati Y, et al. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:203-216.
85. Ince P, Stout N, Shaw P, et al. Parvalbumin and calbindin D28K in human motor system and in motor neuron disease. Neuropathol Appl Neurobiol. 1993;19:291-299.
86. Iacopino A, Christakos S, Modi P, et al. Nerve growth factor increases calcium binding protein (calbindin D28K) in rat olfactory bulb. Brain Res. 1992;578:305-310.
87. Yang S, Wang C, Feng Y. Neurologic and psychiatric manifestations in hypoparathyroidism: clinical analysis of 71 cases. Chin Med J. 1984; 97:267-272.
88. Goswami R, Bhatia M, Goyal R, et al. Reversible peripheral neuropathy in idiopathic hypoparathyroidism. Acta Neurol Scand. 2002;105: 128-131.
89. Gay J, Grimes J. Idiopathic hypoparathyroidism with impaired vitamin B12 absorption and neuropathy. CMAJ. 1972;107:54-56.
90. Dionisi-Vici C, Garavaglia B, Burlina A. Hypoparathyroidism in mitochondrial trifunctional protein deficiency. J Pediatr. 1996;129:159-162.
91. Valensi P, Devehat C, Richard J, et al. A multicenter, double blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy: a preliminary report. J Diabetes Complications. 2005;19:247-253.
92. Goto Y, Hotta N, Shigeta Y, et al. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Biomed Pharmacother. 1995;49:269-277.
93. Hotta N, Sakamoto N, Shigeta Y, et al. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications. 1996;10:168-172.
94. Ikeda T, Iwata K, Tanaka Y. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract. 1999;43:193-198.
95. Okemoto H, Nomura M, Nakaya Y. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med. 2003;42:655-664.
96. Uchida K, Kigoshi T, Nakano S, et al. Effects of 24 weeks of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. Clin Ther. 1995;17:460-466.
97. Kessler M, Ubeaud G, Walter T, et al. Free radical scavenging and skin penetration of troxerutin and vitamin derivatives. J Dermatolog Treat. 2002;13:133-141.
98. Pokorski M, Marczak M, Dymecka A, et al. Ascorbyl palmitate as a carrier of ascorbate into neural tissues. J Biomed Sci. 2003;10:193-198.
99. Bischoff-Ferrari H, Dawson-Hughes B, Willett W, et al. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999-2006.
100. Jackson C, Gaugris S, Sen S, et al. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM. 2007;100:185-192.
101. Kornetti D, Fritz S, Chiu Y, et al. Rating scale analysis of the Berg Balance Scale. Arch Phys Med Rehabil. 2004;85:1128-1135.